Details of the Drug

General Information of Drug (ID: DMBFZ6L)

Drug Name
Remdesivir
Synonyms L-Alanine, N-((S)-hydroxyphenoxyp; RWWYLEGWBNMMLJ-YSOARWBDSA-N; Remdesivir [USAN]; 1809249-37-3; 3QKI37EEHE; AKOS032946252; SB19838; SCHEMBL17712225; UNII-3QKI37EEHE
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Approved [1]
Ebola virus infection 1D60.0 Phase 1 [2]
Middle East Respiratory Syndrome (MERS) 1D64 Investigative [3]
Severe acute respiratory syndrome (SARS) 1D65 Investigative [3]
Affected Organisms
SARS-CoVSARS-CoV-2
ATC Code
J05AB16: Remdesivir
J05AB: Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05A: DIRECT ACTING ANTIVIRALS
J05: ANTIVIRALS FOR SYSTEMIC USE
J: ANTIINFECTIVES FOR SYSTEMIC USE
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 602.6
Logarithm of the Partition Coefficient (xlogp) 1.9
Rotatable Bond Count (rotbonds) 14
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 13
Chemical Identifiers
Formula
C27H35N6O8P
IUPAC Name
2-ethylbutyl (2S)-2-[[[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxyoxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
Canonical SMILES
CCC(CC)COC(=O)[C@H](C)N[P@](=O)(OC[C@@H]1[C@H]([C@H]([C@](O1)(C#N)C2=CC=C3N2N=CN=C3N)O)O)OC4=CC=CC=C4
InChI
InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1
InChIKey
RWWYLEGWBNMMLJ-YSOARWBDSA-N
Cross-matching ID
PubChem CID
121304016
ChEBI ID
CHEBI:145994
CAS Number
1809249-37-3
UNII
3QKI37EEHE
DrugBank ID
DB14761
TTD ID
D01ICI
ACDINA ID
D01380
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
COVID-19 RNA-directed RNA polymerase (RdRp) TTV1095 R1AB_SARS2 (4393-5324) Inhibitor [4]
MERS-CoV RNA-directed RNA polymerase (RdRp) TTOA6YT R1AB_CVEMC (4378-5310) Inhibitor [3]
SARS-CoV RNA-directed RNA polymerase (RdRp) TTKXI53 R1AB_CVHSA (4370-5301) Inhibitor [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Biotransformations [5]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [6]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [6]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Gene/Protein Processing [6]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [6]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Gene/Protein Processing [6]
Cholinesterase (BCHE) OTOH3WQ9 CHLE_HUMAN Biotransformations [5]
Forkhead box protein O3 (FOXO3) OTHXQG4P FOXO3_HUMAN Gene/Protein Processing [6]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Gene/Protein Processing [6]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Biotransformations [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Remdesivir (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Givosiran DM5PFIJ Moderate Increased risk of hepatotoxicity by the combination of Remdesivir and Givosiran. Inborn porphyrin/heme metabolism error [5C58] [7]
Selpercatinib DMZR15V Moderate Increased risk of hepatotoxicity by the combination of Remdesivir and Selpercatinib. Lung cancer [2C25] [7]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrochloric acid E00015 313 Acidulant
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
Betadex sulfobutyl ether sodium E00589 66577045 Solubilizing agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Remdesivir 100mg/20ml solution 100mg/20ml Solution Intravenous
Remdesivir 100mg/vial powder 100mg/vial Powder Intravenous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
4 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.
5 Human carboxylesterase 1A plays a predominant role in the hydrolytic activation of remdesivir in humans. Chem Biol Interact. 2022 Jan 5;351:109744. doi: 10.1016/j.cbi.2021.109744. Epub 2021 Nov 11.
6 An in vitro study on anti-carcinogenic effect of remdesivir in human ovarian cancer cells via generation of reactive oxygen species. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221089257. doi: 10.1177/09603271221089257.
7 Cerner Multum, Inc. "Australian Product Information.".